These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 796807)

  • 21. Modulation of equine platelet function by diethylcarbamazine (DEC).
    Kowalski KA; McConnell LA; Sadoff DA; Leid RW
    Am J Pathol; 1983 Oct; 113(1):1-7. PubMed ID: 6414306
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathways responsible for platelet hypersensitivity in rats with diabetes. I. Streptozocin-induced diabetes.
    Winocour PD; Kinlough-Rathbone RL; Mustard JF
    J Lab Clin Med; 1986 Feb; 107(2):148-53. PubMed ID: 3080538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Failure of certain antiplatelet drugs to affect myointimal thickening following arterial endothelial injury in the rat.
    Clowes AW; Karnovsky MJ
    Lab Invest; 1977 Apr; 36(4):452-64. PubMed ID: 846193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Superoxide dismutase cooperates with prostacyclin to inhibit platelet aggregation: a comparative study in washed platelets and platelet rich plasma.
    Salvemini D; de Nucci G; Vane JR
    Thromb Haemost; 1991 Apr; 65(4):421-4. PubMed ID: 1647553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mechanism of anti-platelet activity of davallialactone: involvement of intracellular calcium ions, extracellular signal-regulated kinase 2 and p38 mitogen-activated protein kinase.
    Kim SD; Lee IK; Lee WM; Cho JY; Park HJ; Oh JW; Park SC; Kim SK; Kwak YS; Yun BS; Rhee MH
    Eur J Pharmacol; 2008 Apr; 584(2-3):361-7. PubMed ID: 18313047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of platelet aggregation by ethanol in vitro shows specificity for aggregating agent used and is influenced by platelet lipid composition.
    Fenn CG; Littleton JM
    Thromb Haemost; 1982 Aug; 48(1):49-53. PubMed ID: 6813995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma components which interfere with ristocetin-induced platelet aggregation.
    Baugh RF; Brown JE; Hougie C
    Thromb Diath Haemorrh; 1975 Jun; 33(3):540-6. PubMed ID: 1080300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of plumbagin on platelet aggregation and platelet-neutrophil interactions.
    Shen Z; Dong Z; Cheng P; Li L; Chen Z; Liu J
    Planta Med; 2003 Jul; 69(7):605-9. PubMed ID: 12898414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Free platelet count and size distribution during C1q inhibition of collagen-induced platelet aggregation.
    Csako G; Suba EA
    Thromb Haemost; 1987 Aug; 58(2):682-5. PubMed ID: 3499680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platelet aggregation and fibrinogen binding in human, rhesus monkey, guinea-pig, hamster and rat blood: activation by ADP and a thrombin receptor peptide and inhibition by glycoprotein IIb/IIIa antagonists.
    Cook NS; Zerwes HG; Tapparelli C; Powling M; Singh J; Metternich R; Hagenbach A
    Thromb Haemost; 1993 Sep; 70(3):531-9. PubMed ID: 8259560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet-collagen interaction. Inhibition by a monoclonal antibody raised against collagen receptor.
    Chiang TM; Jin A; Kang AH
    J Immunol; 1987 Aug; 139(3):887-92. PubMed ID: 3598192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of ethanol on pathways of platelet aggregation in vitro.
    Rand ML; Packham MA; Kinlough-Rathbone RL; Fraser Mustard J
    Thromb Haemost; 1988 Jun; 59(3):383-7. PubMed ID: 3142075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Platelet agonist synergism by the acute phase reactant C-reactive protein.
    Fiedel BA
    Blood; 1985 Feb; 65(2):264-9. PubMed ID: 2578299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of C1q functions by RHP, a protein elevated in sera from patients with rheumatoid arthritis.
    Rosano CL; Braun CB; Hechemy KE; Parhami N; Satoh PS; Hurwitz C
    Complement; 1988; 5(2):57-64. PubMed ID: 3259913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of human platelet activation by polymorphonuclear leukocytes.
    Schattner MA; Geffner JR; Isturiz MA; Lazzari MA
    Br J Pharmacol; 1990 Oct; 101(2):253-6. PubMed ID: 2257433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet aggregation by isolated and aggregated human IgG.
    Palosuo T; Leikola J
    Clin Exp Immunol; 1975 May; 20(2):371-4. PubMed ID: 1212812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C1 and human platelets. II. Detection by immunological methods and role.
    Wautier JL; Tobelem GM; Peltier AP; Caen JP
    Immunology; 1976 Apr; 30(4):459-65. PubMed ID: 818006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of serum proteins on thrombosis and leukocyte adherence on polymer surfaces.
    Barber TA; Lambrecht LK; Mosher DL; Cooper SL
    Scan Electron Microsc; 1979; (3):881-90, 792. PubMed ID: 524058
    [No Abstract]   [Full Text] [Related]  

  • 39. On the reactivity of corneal collagen and subcomponent C1q of the complement system with human platelets and IgG-coated latex particles.
    Csako G; Suba EA; Herp A
    Exp Eye Res; 1983 Mar; 36(3):403-14. PubMed ID: 6601020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies on the mode of reaction of the first component of complement with platelets: interaction between the collagen-like portion of C1q and platelets.
    Wautier JL; Souchon H; Reid KB; Peltier AP; Caen JP
    Immunochemistry; 1977; 14(11-12):763-6. PubMed ID: 202559
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.